OpenOnco
UA EN
Plan Builder Prevention Onco Wiki Tumor Board

Onco Wiki / Red flag

Habitual use of smokeless tobacco products — chewing tobacco, snus (oral nicotine pouch w...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDRF-LIFESTYLE-SMOKELESS-TOBACCO-PREVENTION
TypeRed flag
Statusreviewed 2026-05-19 | pending_clinical_signoff
DiseasesDIS-ESOPHAGEAL DIS-HNSCC DIS-PDAC
SourcesSRC-IARC-100A-TOBACCO-SMOKING

Red Flag Origin

DefinitionHabitual use of smokeless tobacco products — chewing tobacco, snus (oral nicotine pouch with tobacco), snuff (dry, moist, dipping tobacco), gutka/pan masala (South Asian preparations with areca nut + tobacco). IARC Group 1 carcinogen (Monograph 89, 2007; reaffirmed Monograph 100E). Causally linked to oral cavity cancer (tongue, gum, buccal mucosa, floor of mouth — particularly at the placement site), esophageal cancer, pancreatic cancer (RR ~1.5-2.0 in Northern European snus cohorts; meta-analyses Boffetta + Hashibe 2008). Risk of oral cancer markedly elevated in South-Asian gutka/pan masala users — RR up to ~10 with combined tobacco + areca nut + lime. Cessation reduces risk over time but not to baseline non-user levels; oral mucosa changes (leukoplakia, erythroplakia) can regress with cessation. Prevention-persona RedFlag (§20 v0.3 lifestyle expansion).
Clinical directioninvestigate
Categoryother

Trigger Logic

{
  "any_of": [
    {
      "finding": "smokeless_tobacco_current_use",
      "value": true
    },
    {
      "finding": "chewing_tobacco_daily_use",
      "value": true
    },
    {
      "finding": "snus_current_use",
      "value": true
    },
    {
      "finding": "gutka_pan_masala_use",
      "value": true
    },
    {
      "finding": "smokeless_tobacco_former_long_term",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notes

Prevention-persona RedFlag for smokeless tobacco. Most modifiable cancer exposure in users; cessation pharmacotherapy (nicotine replacement, varenicline) is effective. Oral examination at every encounter; biopsy any leukoplakia/erythroplakia >2 weeks; visual inspection with toluidine blue or autofluorescence in high-burden settings. STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode.

Used By

Indications